Author

Kata Szántó

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

Kata Szántó  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE
MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE

Kata Szántó  et al.

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Kata Szántó  et al.

COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS
COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS

Kata Szántó  et al.

TRANSFORMATION OF FECAL MICROBIOTA COMPOSITION DUE TO BOWEL PREPARATION WITH MAGNESIUM-OXID AND SODIUM PICOSULFATE AMONGST PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TRANSFORMATION OF FECAL MICROBIOTA COMPOSITION DUE TO BOWEL PREPARATION WITH MAGNESIUM-OXID AND SODIUM PICOSULFATE AMONGST PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Kata Szántó  et al.

COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS

Kata Szántó  et al.

CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS
CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS

Kata Szántó  et al.

CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE
CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE

Kata Szántó  et al.

QUALITY INDICATORS AND RESULTS OF COLONOSCOPY EXAMINATIONS IN THE FIRST YEAR OF HUNGARIAN POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM - A NATIONWIDE COHORT STUDY
QUALITY INDICATORS AND RESULTS OF COLONOSCOPY EXAMINATIONS IN THE FIRST YEAR OF HUNGARIAN POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM - A NATIONWIDE COHORT STUDY

Kata Szántó  et al.

INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE
INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE

Kata Szántó  et al.

FIRST-YEAR ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS
FIRST-YEAR ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS

Kata Szántó  et al.

IBD-RELATED MALIGNANCIES OBSERVED IN 2015-2019 - 4 YEARS' RESULTS FROM THE PROSPECTIVE, NATIONWIDE HUNGARIAN REGISTRY
IBD-RELATED MALIGNANCIES OBSERVED IN 2015-2019 - 4 YEARS' RESULTS FROM THE PROSPECTIVE, NATIONWIDE HUNGARIAN REGISTRY

Kata Szántó  et al.

POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES

Kata Szántó  et al.

INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE
INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE

Kata Szántó  et al.

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

Kata Szántó  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Kata Szántó  et al.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE
SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Kata Szántó  et al.

Item 1 - 18 / 18
1